EFFICACY, SAFETY, AND TOLERABILITY OF AFQ056 FOR THE TREATMENT OF CHOREA IN PATIENTS WITH HUNTINGTON'S DISEASE

被引：0
|
作者：
Reilmann, R. [1 ,2 ]
Rouzade-Dominguez, M. [3 ]
Saft, C. [4 ]
Suessmuth, S. D. [5 ]
Priller, J. [6 ]
Rosser, A. [7 ,8 ]
Rickards, H. [9 ]
Schoels, L. [10 ]
Pezous, N. [11 ]
Gasparini, F. [12 ]
Landwehrmeyer, G. B. [5 ]
Johns, D. [13 ]
Gomez-Mancilla, B. [12 ]
机构：
[1] George Huntington Inst, D-48149 Munster, Germany
[2] Univ Munster, Dept Neurol, D-48149 Munster, Germany
[3] Novartis Pharma AG, Clin Sci & Innovat, CH-4056 Basel, Switzerland
[4] Ruhr Univ Bochum, Neurol Klin, D-44791 Bochum, Germany
[5] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany
[6] Charite, Dept Neuropsychiat, D-10117 Berlin, Germany
[7] Cardiff Univ, Sch Med, Neurosci & Mental Hlth Res Inst, Cardiff CF10 3AX, S Glam, Wales
[8] Cardiff Univ, Sch Biosci, Neurosci & Mental Hlth Res Inst, Cardiff CF10 3AX, S Glam, Wales
[9] Barberry, Dept Neuropsychiat, Birmingham B15 2FG, W Midlands, England
[10] Inst Clin Brain Res, Ctr Neurol & Hertie, Clin Neurogenet Unit, D-72076 Tubingen, Germany
[11] Novartis Pharma AG, IIS Translat Sci Early Dev Stat Res, CH-4002 Basel, Switzerland
[12] Novartis Pharma AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland
[13] Novartis Inst Biomed Res Inc, Neurosci Translat Med, Cambridge, MA 02139 USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2014年 / 85卷
关键词：
D O I：
10.1136/jnnp-2014-309032.295
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
N03
引用
收藏
页码：A102 / A103
页数：3
相关论文
共 50 条
  • [1] A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease
    Reilmann, Ralf
    Rouzade-Dominguez, Marie-Laure
    Saft, Carsten
    Suessmuth, Sigurd D.
    Priller, Josef
    Rosser, Anne
    Rickards, Hugh
    Schoels, Ludger
    Pezous, Nicole
    Gasparini, Fabrizio
    Johns, Donald
    Landwehrmeyer, Georg Bernhard
    Gomez-Mancilla, Baltazar
    MOVEMENT DISORDERS, 2015, 30 (03) : 427 - 431
  • [2] Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
    Kumar, Rajeev
    Hauser, Robert A.
    Mostillo, Joseph
    Dronamraju, Nalina
    Graf, Ana
    Merschhemke, Martin
    Kenney, Christopher
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (01) : 20 - 24
  • [3] Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
    Ahmed Negida
    Hazem S. Ghaith
    Salma Yousry Fala
    Hussien Ahmed
    Eshak I Bahbah
    Mahmoud Ahmed Ebada
    Mohamed Abd Elalem Aziz
    Neurological Sciences, 2021, 42 : 3135 - 3143
  • [4] Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis
    Negida, Ahmed
    Ghaith, Hazem S.
    Fala, Salma Yousry
    Ahmed, Hussien
    Bahbah, Eshak, I
    Ebada, Mahmoud Ahmed
    Aziz, Mohamed Abd Elalem
    NEUROLOGICAL SCIENCES, 2021, 42 (08) : 3135 - 3143
  • [5] Mavoglurant (AFQ056) for the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease: A Pooled Analysis of 485 Patients' Data
    Negida, Ahmed
    Fala, Salma
    Bahbah, Eshak
    MOVEMENT DISORDERS, 2018, 33 : S35 - S35
  • [6] EFFICACY AND SAFETY OF TIAPRIDE FOR CHOREA TREATMENT IN HUNTINGTON'S DISEASE: A SYSTEMATIC REVIEW
    Feleus, Stephanie
    van Schaijk, Malu
    Roos, Raymund A. C.
    de Bot, Susanne
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 : A54 - A54
  • [7] TREATMENT OF CHOREA AND ITS EFFICACY IN HUNTINGTON'S DISEASE (HD) PATIENTS
    Cichecki, Filip
    Witkowski, Grzegorz
    Zielonka, Daniel
    Sienkiewicz-Jarosz, Halina
    Stepniak, Iwona
    Ziora-Jakutowicz, Karolina
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A72 - A72
  • [8] AFQ056 treatment of severe levodopa-induced dyskinesias: Proof of concept study
    Berg, D.
    Godau, J.
    Trenkwalder, C.
    Eggert, K.
    Csoti, I.
    Storch, A.
    Gasparini, F.
    Hariry, S.
    Vandemeulebroecke, M.
    Johns, D.
    Gomez-Mancilla, B.
    MOVEMENT DISORDERS, 2010, 25 (07) : S290 - S290
  • [9] A 6-week, double-blind, multicenter RCT in Parkinson's disease patients to explore the efficacy and safety of AFQ056 when combined with increased doses of L-dopa
    Kumar, R.
    Hauser, R. A.
    Mostillo, J.
    Dronamraju, N.
    Graf, A.
    Merschhemke, M.
    MOVEMENT DISORDERS, 2012, 27 : S126 - S126
  • [10] AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome
    Levenga, Josien
    Hayashi, Shigemi
    de Vrij, Femke M. S.
    Koekkoek, Sebastiaan K.
    van der Linde, Herma C.
    Nieuwenhuizen, Ingeborg
    Song, Cheng
    Buijsen, Ronald A. M.
    Pop, Andreea S.
    GomezMancilla, Baltazar
    Nelson, David L.
    Willemsen, Rob
    Gasparini, Fabrizio
    Oostra, Ben A.
    NEUROBIOLOGY OF DISEASE, 2011, 42 (03) : 311 - 317
12345